BRPI0815567B8 - anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica - Google Patents

anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica

Info

Publication number
BRPI0815567B8
BRPI0815567B8 BRPI0815567A BRPI0815567A BRPI0815567B8 BR PI0815567 B8 BRPI0815567 B8 BR PI0815567B8 BR PI0815567 A BRPI0815567 A BR PI0815567A BR PI0815567 A BRPI0815567 A BR PI0815567A BR PI0815567 B8 BRPI0815567 B8 BR PI0815567B8
Authority
BR
Brazil
Prior art keywords
integrin
alpha
antibodies
pharmaceutical composition
fusion protein
Prior art date
Application number
BRPI0815567A
Other languages
English (en)
Inventor
Hahn Diane
Mitjans Francesc
Adan Jaume
Lo Kin-Ming
Goodman Simon
Original Assignee
Merck Patent Gessellschaft Mit Beschraenkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gessellschaft Mit Beschraenkter Haftung filed Critical Merck Patent Gessellschaft Mit Beschraenkter Haftung
Publication of BRPI0815567A2 publication Critical patent/BRPI0815567A2/pt
Publication of BRPI0815567B1 publication Critical patent/BRPI0815567B1/pt
Publication of BRPI0815567B8 publication Critical patent/BRPI0815567B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

anticorpos híbridos anti-alfa v-integrina projetados. a presente invenção se refere a anticorpos projetados que se ligam especificamente a receptores integrinas, especialmente à subunidade de receptor alfa v integrina. os anticorpos compreendem os locais de ligação de antígeno (c-drs) de um anticorpo anti-integrina de camundongo conhecido, bem como sequências variáveis de cadeia leve híbrida, sequências variáveis de cadeia pesada mutacionada (frs) e sequências constantes de cadeia pesada modificadas. os novos anticorpos têm propriedades imunogênicas e de expressão aperfeiçoadas e induzem excelente atividades antiangiogênico bem como atividades antitumor em humanos em monoterapia, mas também, e acima de tudo, em combinação com outros agentes de inibição de angiogênese e de tumor.
BRPI0815567A 2007-07-17 2008-07-17 anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica BRPI0815567B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07013964.7 2007-07-17
EP07013964 2007-07-17
PCT/EP2008/005852 WO2009010290A2 (en) 2007-07-17 2008-07-17 Engineered anti-alpha v- integrin hybrid antibodies

Publications (3)

Publication Number Publication Date
BRPI0815567A2 BRPI0815567A2 (pt) 2015-02-18
BRPI0815567B1 BRPI0815567B1 (pt) 2019-06-04
BRPI0815567B8 true BRPI0815567B8 (pt) 2021-05-25

Family

ID=40029330

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815567A BRPI0815567B8 (pt) 2007-07-17 2008-07-17 anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica

Country Status (20)

Country Link
US (1) US8562986B2 (pt)
EP (2) EP2167128B1 (pt)
JP (1) JP5341889B2 (pt)
KR (1) KR101559596B1 (pt)
CN (1) CN101687039B (pt)
AU (1) AU2008277907B2 (pt)
BR (1) BRPI0815567B8 (pt)
CA (1) CA2693863C (pt)
CY (1) CY1113493T1 (pt)
DK (1) DK2167128T3 (pt)
EA (1) EA019485B1 (pt)
ES (1) ES2395799T3 (pt)
HK (1) HK1143523A1 (pt)
HR (1) HRP20120949T1 (pt)
IL (1) IL203269A (pt)
PL (1) PL2167128T3 (pt)
PT (1) PT2167128E (pt)
SI (1) SI2167128T1 (pt)
WO (1) WO2009010290A2 (pt)
ZA (1) ZA201001124B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101717304B1 (ko) 2008-12-23 2017-03-16 메르크 파텐트 게엠베하 항-혈관생성 활성이 있는 저해제에 대한 바이오마커
KR101606236B1 (ko) * 2009-08-19 2016-03-24 메르크 파텐트 게엠베하 Ｆｆｐｅ 물질 내의 인테그린 복합체의 검출용 항체
CN103347540B (zh) * 2011-02-11 2016-05-25 默克专利股份公司 用于治疗前列腺癌的抗-α-v整联蛋白抗体
EP3041863A4 (en) * 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
CA2961421C (en) 2014-09-17 2024-01-30 Merck Patent Gmbh A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
WO2016041616A1 (en) 2014-09-17 2016-03-24 Merck Patent Gmbh A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
MX2017006323A (es) 2014-11-21 2017-08-21 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
CN113773388A (zh) 2014-11-21 2021-12-10 百时美施贵宝公司 抗cd73抗体及其用途
MX2018006269A (es) * 2015-11-23 2018-09-05 Merck Patent Gmbh Anticuerpo anti-alfa-v-integrina para el tratamiento de fibrosis y/o trastornos fibroticos.
JP7034914B2 (ja) 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
JP2019533139A (ja) 2016-09-08 2019-11-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ネフローゼ症候群を診断及び処置するための方法
CN110087530A (zh) 2016-12-07 2019-08-02 普罗根尼蒂公司 胃肠道检测方法、装置和系统
EP4233902A3 (en) 2016-12-14 2024-02-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
MX2019007984A (es) 2017-02-02 2019-10-15 Merck Patent Gmbh Apareamiento preferido de dominios de anticuerpos.
CN108948206B (zh) * 2017-05-23 2022-08-23 赵磊 一种抗egfr/pd-1双靶向抗体、其制备方法及用途
US11623963B2 (en) 2017-10-03 2023-04-11 Merck Patent Gmbh Cysteine engineered antigen-binding molecules
WO2019089544A1 (en) * 2017-11-01 2019-05-09 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
AU2019362602A1 (en) 2018-10-19 2021-06-03 Merck Patent Gmbh Abituzumab for the treatment of colorectal cancer
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN114366749B (zh) * 2020-10-15 2023-06-30 中国人民解放军海军军医大学 整合素抑制剂在制备治疗肾癌的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ282603B6 (cs) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
PT719859E (pt) 1994-12-20 2003-11-28 Merck Patent Gmbh Anticorpo monoclonal anti-alfa v-integrina
JP3461945B2 (ja) 1994-12-26 2003-10-27 株式会社日本製鋼所 高低圧一体型タービンロータの製造方法
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
JP2002534959A (ja) 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
ATE400030T1 (de) 2001-02-19 2008-07-15 Merck Patent Gmbh Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenität
JP4741242B2 (ja) * 2002-11-26 2011-08-03 アボット バイオセラピューティクス コーポレイション 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
KR20060002667A (ko) 2004-07-03 2006-01-09 삼성전자주식회사 디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브
BRPI0620795A2 (pt) 2005-12-30 2011-11-22 Merck Patent Ges Mit Beschronkter Haftung anticorpos anti-cd19 imunogenicidade reduzida
WO2007084620A2 (en) 2006-01-19 2007-07-26 Bassler G Scott Rapid food chiller

Also Published As

Publication number Publication date
BRPI0815567A2 (pt) 2015-02-18
CN101687039B (zh) 2014-04-16
CY1113493T1 (el) 2016-06-22
EP2167128B1 (en) 2012-10-24
BRPI0815567B1 (pt) 2019-06-04
WO2009010290A3 (en) 2009-04-09
US20100254977A1 (en) 2010-10-07
CA2693863C (en) 2017-10-03
HRP20120949T1 (en) 2012-12-31
WO2009010290A2 (en) 2009-01-22
DK2167128T3 (da) 2012-12-03
HK1143523A1 (en) 2011-01-07
EA201070150A1 (ru) 2010-08-30
PT2167128E (pt) 2013-01-24
EA019485B1 (ru) 2014-04-30
SI2167128T1 (sl) 2013-01-31
EP2526967A1 (en) 2012-11-28
KR20100057010A (ko) 2010-05-28
CA2693863A1 (en) 2009-01-22
EP2167128A2 (en) 2010-03-31
AU2008277907A1 (en) 2009-01-22
JP5341889B2 (ja) 2013-11-13
KR101559596B1 (ko) 2015-10-12
ZA201001124B (en) 2010-11-24
IL203269A (en) 2014-11-30
AU2008277907B2 (en) 2013-08-22
ES2395799T3 (es) 2013-02-15
CN101687039A (zh) 2010-03-31
JP2010533480A (ja) 2010-10-28
PL2167128T3 (pl) 2013-03-29
US8562986B2 (en) 2013-10-22

Similar Documents

Publication Publication Date Title
BRPI0815567B8 (pt) anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica
CY1120412T1 (el) Μορια εξανθρωπισμενου αντισωματος ειδικα για il-31
ES2683847T3 (es) Inmunoglobulina citotóxica
DOP2013000045A (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
CL2017003351A1 (es) Anticuerpo anti receptor de transferrina humana que pasan a través de la barrera hematoencefálica.
CL2013000843A1 (es) Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso.
AR099812A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
AR073538A1 (es) Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
AR075896A1 (es) Anticuerpos anti-her (factor de crecimiento epidermico)
CL2014003465A1 (es) Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer.
PE20221007A1 (es) Anticuerpos anti-receptor de transferrina con afinidad disenada
PA8847001A1 (es) Anticuerpos humanos de alta afinidad para el receptor il-4-humano
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
GT201700102A (es) Conjugados de anticuerpo-fármaco
AR091961A1 (es) Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b)
PE20091024A1 (es) Anticuerpos monoclonales que se unen a anexelekto y sus usos
AR076195A1 (es) Anticuerpos biespecificos anti-erbb-1/anti-c-met
CR20140585A (es) Proteinas de union a antigeno st2
CL2012001387A1 (es) Anticuerpos murinos, humanizados o fragmentos de ellos anti-receptor epha2; conjugados citotoxicos; composiciones farmaceuticas que los contienen; secuencias nucleotidicas; vector; celula huesped e hibridomas que los producen y el uso de los anticuerpos en el tratamiento del cancer como en metodos de diagnostico. (divisional de sol. n° 2085-07)
PE20160690A1 (es) Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
EA201270769A1 (ru) Антитела к cgrp
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
MX2012006406A (es) Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
CR20130016A (es) ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
AR064464A1 (es) Anticuerpos anti - receptor del factor de crecimiento insulinico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF